Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.

Aberrant signaling through insulin (Ins) and insulin-like growth factor I (IGF1) receptors contribute to the risk and advancement of many cancer types by activating cell survival cascades. Similarities between these pathways have thus far prevented the development of pharmacological interventions th...

Full description

Bibliographic Details
Main Authors: Cemal Erdem, Adrian V Lee, D Lansing Taylor, Timothy R Lezon
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-06-01
Series:PLoS Computational Biology
Online Access:https://doi.org/10.1371/journal.pcbi.1009125
id doaj-5a50932ee04e4320af6e668981cb0eb3
record_format Article
spelling doaj-5a50932ee04e4320af6e668981cb0eb32021-07-24T04:32:00ZengPublic Library of Science (PLoS)PLoS Computational Biology1553-734X1553-73582021-06-01176e100912510.1371/journal.pcbi.1009125Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.Cemal ErdemAdrian V LeeD Lansing TaylorTimothy R LezonAberrant signaling through insulin (Ins) and insulin-like growth factor I (IGF1) receptors contribute to the risk and advancement of many cancer types by activating cell survival cascades. Similarities between these pathways have thus far prevented the development of pharmacological interventions that specifically target either Ins or IGF1 signaling. To identify differences in early Ins and IGF1 signaling mechanisms, we developed a dual receptor (IGF1R & InsR) computational response model. The model suggested that ribosomal protein S6 kinase (RPS6K) plays a critical role in regulating MAPK and Akt activation levels in response to Ins and IGF1 stimulation. As predicted, perturbing RPS6K kinase activity led to an increased Akt activation with Ins stimulation compared to IGF1 stimulation. Being able to discern differential downstream signaling, we can explore improved anti-IGF1R cancer therapies by eliminating the emergence of compensation mechanisms without disrupting InsR signaling.https://doi.org/10.1371/journal.pcbi.1009125
collection DOAJ
language English
format Article
sources DOAJ
author Cemal Erdem
Adrian V Lee
D Lansing Taylor
Timothy R Lezon
spellingShingle Cemal Erdem
Adrian V Lee
D Lansing Taylor
Timothy R Lezon
Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.
PLoS Computational Biology
author_facet Cemal Erdem
Adrian V Lee
D Lansing Taylor
Timothy R Lezon
author_sort Cemal Erdem
title Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.
title_short Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.
title_full Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.
title_fullStr Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.
title_full_unstemmed Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.
title_sort inhibition of rps6k reveals context-dependent akt activity in luminal breast cancer cells.
publisher Public Library of Science (PLoS)
series PLoS Computational Biology
issn 1553-734X
1553-7358
publishDate 2021-06-01
description Aberrant signaling through insulin (Ins) and insulin-like growth factor I (IGF1) receptors contribute to the risk and advancement of many cancer types by activating cell survival cascades. Similarities between these pathways have thus far prevented the development of pharmacological interventions that specifically target either Ins or IGF1 signaling. To identify differences in early Ins and IGF1 signaling mechanisms, we developed a dual receptor (IGF1R & InsR) computational response model. The model suggested that ribosomal protein S6 kinase (RPS6K) plays a critical role in regulating MAPK and Akt activation levels in response to Ins and IGF1 stimulation. As predicted, perturbing RPS6K kinase activity led to an increased Akt activation with Ins stimulation compared to IGF1 stimulation. Being able to discern differential downstream signaling, we can explore improved anti-IGF1R cancer therapies by eliminating the emergence of compensation mechanisms without disrupting InsR signaling.
url https://doi.org/10.1371/journal.pcbi.1009125
work_keys_str_mv AT cemalerdem inhibitionofrps6krevealscontextdependentaktactivityinluminalbreastcancercells
AT adrianvlee inhibitionofrps6krevealscontextdependentaktactivityinluminalbreastcancercells
AT dlansingtaylor inhibitionofrps6krevealscontextdependentaktactivityinluminalbreastcancercells
AT timothyrlezon inhibitionofrps6krevealscontextdependentaktactivityinluminalbreastcancercells
_version_ 1721284350278893568